IP Library Patent Application 13152882
Patent Application
App. No. 13/152,882

USE OF A CONTAINER OF AN INORGANIC ADDITIVE CONTAINING PLASTIC MATERIAL

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/152,882
Abstract

The present invention relates to the use of a container, made of an inorganic additive containing plastic material, for reducing physical/chemical interaction between the container and an oil, fat and/or wax containing formulation contained therein.

Claims (31)

1 - 12 . (canceled)

13 . A method for reducing physical/chemical interaction between a plastic container and a lipophilic testosterone gel formulation, comprising:

(a) adding an inorganic additive to a plastic material during manufacture; and

(b) exposing the plastic container to the formulation;

wherein the lipophilic testosterone gel formulation comprises testosterone and at least one oil, fat, wax, lipophilic or partially lipophilic carrier; and a compound or a mixture of compounds having surface tension decreasing activity, in an amount effective for in situ generation of an emulsion upon contact of the formulation with water; and

wherein the lipophilic testosterone gel formulation is used for mammalian nasal application.

14 . The method according to claim 13 wherein the physical/chemical interaction is an adsorption of the formulation to the plastic material.

15 . The method according to claim 13 , wherein the inorganic additive is at least a pigment.

16 . The method according to claim 15 , wherein said pigment is selected from the group consisting of titanium dioxide (TiO 2 ), surface-treated titanium dioxide, or a mixture thereof

17 . The method according to claim 13 , wherein the additive is present in the plastic material in an amount between about 0.1 and about 10% by weight based on the weight of the plastic material.

18 . The method according to claim 13 , wherein the plastic material comprises polyolefin.

19 . The method according to claim 18 , wherein the polyolefin is selected from the group of polyethylene, polypropylene, copolymers of ethylene and propylene, or a mixture thereof.

20 . The method according to claim 19 , wherein the plastic material comprises low density polyethylene (LDPE).

21 . The method according to claim 13 , wherein the plastic material is suitable for extrusion blow molding.

22 . The method according to claim 13 , wherein the additive is present in the plastic material in an amount between about 0.1% to about 5% by weight based on the weight of the plastic material.

23 . The method according to claim 13 , wherein the additive is present in the plastic material in an amount of about 2% by weight based on the weight of the plastic material.

24 . The method of claim 13 , wherein the plastic container extends the shelf life and stability of the formulation for a period of time longer than that of a plastic container without the addition of the inorganic additive.

25 . A method for reducing physical or chemical interaction between a plastic container and a lipophilic testosterone gel formulation, comprising:

(a) adding to a plastic material comprising polyolefin titanium dioxide (TiO2) in an amount between about 0.1 and about 10% by weight, based on the weight of the plastic material; and

(b) exposing the plastic container to the formulation;

wherein the lipophilic formulation comprises (i) at least one steroid hormone dissolved or suspended in an oil, fat, wax, lipophilic or partially lipophilic carrier, and (ii) a compound or a mixture of compounds having surface tension decreasing activity, in an amount effective for in situ generation of an emulsion upon contact of the formulation with water;

wherein the formulation is used for mammalian nasal application; and

wherein the plastic container extends the shelf life and stability of the formulation for a period of time longer than that of a plastic container without the addition of titanium dioxide (TiO2).

26 . The method according to claim 25 , wherein the polyolefin is selected from the group of polyethylene, polypropylene, copolymers of ethylene and propylene and mixtures thereof.

27 . The method according to 25, wherein the plastic material comprises low density polyethylene (LDPE).

28 . The method according to claim 25 , wherein the plastic material is suitable for extrusion blow molding.

29 . The method according to claim 25 , wherein the titanium dioxide (TiO2) is surface-treated titanium dioxide.

30 . The method according to claim 25 , wherein the titanium dioxide (TiO2) is mixed with surface-treated titanium dioxide.

31 . The method according to claim 25 , wherein the titanium dioxide (TiO2) is present in the plastic material in an amount of between about 0.1% to about 5% by weight based on the weight of the plastic material.

32 . The method according to claim 25 , wherein the titanium dioxide (TiO2) is present in the plastic material in an amount of about 2% by weight based on the weight of the plastic material.

33 . The method according to claim 25 , wherein the amount of the testosterone remaining in the lipophilic testosterone gel formulation after long-term storage is about 100%, wherein the percentage of the remaining drug is determined by high performance liquid chromatography (HPLC) technique.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 9, 2018
From: MIDCAP FUNDING V TRUST
To: ACERUS PHARMACEUTICALS SRL
Reel/Frame 047207/0254 →
CORRECTIVE ASSIGNMENT TO CORRECT THE TO CORRECT THE ASSIGNOR FROM M & P PATNT AKTIENGESELLSCHAFT TO M & P PATENT AKTIENGESELLSCHAFT PREVIOUSLY RECORDED ON REEL 032291 FRAME 0349. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER EFFECTIVE 02/04/2014. Recorded Mar 10, 2014
From: M & P PATENT AKTIENGESELLSCHAFT
To: MATTERN PHARMA AG
Reel/Frame 032422/0169 →
MERGER Recorded Feb 25, 2014
From: M & P PATNT AKTIENGESELLSCHAFT
To: MATTERN PHARMA AG
Reel/Frame 032291/0349 →